Funding Opportunity PA-17-446 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites Exploratory/Developmental Research Grant (R21) applications that propose to study the ethical, legal and social implications (ELSI) of human genome research. These applications should propose single or mixed methods studies that break new ground, extend previous discoveries in new directions or develop preliminary data in preparation for larger studies. Of particular interest are studies that explore the implications of new or emerging genomic technologies or novel uses of genomic information.

Funding Opportunity RFA-RM-17-011 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) addresses the need for a robust National Metabolomics Data Repository to store, and make publicly available, raw and processed metabolomic data generated by large NIH programs, individual research grants, and other biomedical research groups. Data, associated metadata, and the essential tools critical for accessing the key information will be housed in a cloud computing environment accessible for searching and reanalysis by the biomedical research community. The Metabolomics Data Repository and Coordination Center (DRCC), created in Stage I of the Common Fund Metabolomics Program, has begun to address this need. In the transition to a National Metabolomics Data Repository, the successful applicant is expected to continue and enhance the current technical capabilities of the Data Repository and create a governance structure that engages the wider metabolomics community to guide the repositorys efforts toward continual technical improvement and expansion and policy development for data deposition, access, and citation.

Funding Opportunity RFA-RM-17-012 from the NIH Guide for Grants and Contracts. The goal of this cooperative agreement Funding Opportunity Announcement (FOA) is to address key challenges in analyzing and interpreting metabolomics data by developing novel tools to facilitate metabolomics data analysis and interpretation. Specifically, successful awardees will develop new or enhanced computational approaches or tools that facilitate metabolomics data analysis, interpretation, and integration. Generalizable, scalable, and portable solutions appropriate for scientists with limited expertise in informatics are particularly encouraged. Projects are not intended to supplement ongoing metabolomics analyses, but to provide tools for broader use by the biomedical research community.

Funding Opportunity RFA-RM-17-013 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites applications to establish Compound Identification Development Cores (CIDC) to develop innovative approaches to enhance compound identification of the most significant, biomedically-relevant unknown metabolites. The ultimate goal of this FOA is to expand the repertoire of biologically relevant compounds that can be quickly and inexpensively identified in high throughput metabolomics experiments. An interdisciplinary approach and partnership among metabolomics experts, biomedical researchers, chemists, and computational experts will be integral to the success of this goal, and advances made through this initiative are expected to be catalytic to the field.

Funding Opportunity RFA-RM-17-014 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) solicits applications to establish a Stakeholder Engagement and Program Coordination Center (SEPCC) to coordinate the required activities of the Common Fund Metabolomics Program Consortium; to engage the stakeholder community in identifying and developing strategies to address outstanding concerns in the application of metabolomics to biomedical research; and to promote use of Consortium resources by the greater biomedical research community. The Common Fund Metabolomics Program views community engagement and multi-directional communication as essential to overcome challenges in realizing the potential of metabolomics in biomedical research.

Notice NOT-DA-17-051 from the NIH Guide for Grants and Contracts

Funding Opportunity PA-17-442 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) encourages administrative supplements for the NINDS Research Education Program for Residents and Fellows in Neurology, Neurosurgery, Neuropathology, Neuroradiology and Emergency Medicine (R25, PAR-13-384 and subsequent reissuances)

Notice NOT-HD-17-015 from the NIH Guide for Grants and Contracts

Notice NOT-HD-17-018 from the NIH Guide for Grants and Contracts

Notice NOT-MH-17-040 from the NIH Guide for Grants and Contracts

Notice NOT-NS-17-037 from the NIH Guide for Grants and Contracts

Notice NOT-HL-17-529 from the NIH Guide for Grants and Contracts

Notice NOT-EB-17-006 from the NIH Guide for Grants and Contracts

Notice NOT-EB-17-005 from the NIH Guide for Grants and Contracts

Funding Opportunity PAR-17-439 from the NIH Guide for Grants and Contracts. The National Institute of Allergy and Infectious Diseases (NIAID) announces a program that provides NIAID-supported K01, K08, and K23 recipients with the opportunity to apply for Small Research Grant (R03) support at some point during the final two years of their K award. Through the use of this mechanism, NIAID seeks to enhance the capability of its K01, K08, and K23 award recipients to conduct research as they complete their transition to fully independent investigator status (e.g., R01 support). The R03 grant mechanism supports different types of projects, including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology. The R03 is, therefore, intended to support research projects that can be carried out in a short period of time with limited resources and that may provide preliminary data to support a subsequent R01, or equivalent, application.

Funding Opportunity RFA-AG-18-016 from the NIH Guide for Grants and Contracts. The overall goal of this funding announcement is to elicit applications for novel strategies to enhance referral, participation, and adherence in cardiac rehabilitation (CR) of older and vulnerable patients who are eligible for CR under current Medicare eligibility criteria. Specifically, NIA seeks clinical trials that address one or more specific age-related factors including patient-related issues, CR program goals and components, and CR program setting-related aspects. These three age-related issues represent distinct, but potentially interrelated, areas that are impacted by advancing age and are not currently addressed in traditional CR programs. Determination of the specific aspects of CR programs that may be better suited to medically complex and vulnerable older adults, such as eligibility, patient-centered goals and outcomes, and novel components and delivery systems may ultimately improve referral, enrollment, completion and overall benefit of this Medicare-supported resource. Successful modified programs should strive to improve function, independence and quality of life while reducing disability, future CV events, readmissions, morbidity and mortality.

Funding Opportunity PAR-17-438 from the NIH Guide for Grants and Contracts. Through this funding opportunity announcement (FOA), NIH wishes to stimulate research in discovery and development of novel, small molecules for their potential use in studying disease treatment relevant to the missions of the participating NIH Institutes; and to generate new insight into the biology of relevant diseases and processes that have yet to be validated as important drug targets.

Notice NOT-HD-17-012 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-HG-17-008 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites applications to participate in the Implementing Genomics in Practice (IGNITE) II: Pragmatic Clinical Trials Network. This network will conduct pragmatic clinical trials to measure the clinical utility and cost-effectiveness of genomic medicine interventions; assess approaches for real-world application of genomic medicine in diverse clinical settings; and produce generalizable knowledge on the types of genomic medicine interventions requiring randomized clinical trials and effective methods for conducting them. Applicants to this FOA are expected to recruit a minimum of 35% of patients who come from racial or ethnic minority populations, underserved populations, or populations who experience poorer medical outcomes. In contrast, applicants to the companion RFA HG-17-009 are expected to recruit a minimum of 75% of such patients.

Funding Opportunity RFA-HG-17-009 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites applications to participate in the Implementing Genomics in Practice (IGNITE) II: Pragmatic Clinical Trials Network. This network will conduct pragmatic clinical trials to measure the clinical utility and cost-effectiveness of genomic medicine interventions; assess approaches for real-world application of genomic medicine in diverse clinical settings; and produce generalizable knowledge on the types of genomic medicine interventions requiring randomized clinical trials and effective methods for conducting them. Applicants to this FOA are expected to recruit a minimum of 75% of patients who come from racial or ethnic minority populations, underserved populations, or populations who experience poorer medical outcomes. In contrast, applicants to the companion RFA HG-17-008 are expected to recruit a minimum of 35% of such patients.